Literature DB >> 19486800

Systemic adverse events after bevacizumab.

Daniel B Roth, Alex King, Meredith Weiss, Daniel Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19486800     DOI： 10.1016/j.ophtha.2009.02.011

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  5 in total

Review 1.  Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review.

Authors:  Taygan Yilmaz; Miguel Cordero-Coma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-27       Impact factor: 3.117

2.  Reversible myocardial dysfunction following intraocular bevacizumab administration.

Authors:  Srikanth C Penumetsa; Mohammad Z Hoque; Gregory Giugliano
Journal:  J Cardiovasc Dis Res       Date:  2013-02-27

Review 3.  A review of anti-VEGF agents for proliferative diabetic retinopathy.

Authors:  P Osaadon; X J Fagan; T Lifshitz; J Levy
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

Review 4.  The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.

Authors:  Gemma Tremolada; Claudia Del Turco; Rosangela Lattanzio; Silvia Maestroni; Anna Maestroni; Francesco Bandello; Gianpaolo Zerbini
Journal:  Exp Diabetes Res       Date:  2012-04-11

5.  Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration.

Authors:  Gebran Khneizer; Ahmad Al-Taee; Bahar Bastani
Journal:  J Nephropathol       Date:  2017-02-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.